CN101647943B - Medicinal composition - Google Patents
Medicinal composition Download PDFInfo
- Publication number
- CN101647943B CN101647943B CN2008101181437A CN200810118143A CN101647943B CN 101647943 B CN101647943 B CN 101647943B CN 2008101181437 A CN2008101181437 A CN 2008101181437A CN 200810118143 A CN200810118143 A CN 200810118143A CN 101647943 B CN101647943 B CN 101647943B
- Authority
- CN
- China
- Prior art keywords
- radix
- radix rehmanniae
- weight portions
- bombyx batryticatus
- medicinal composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention discloses a medicinal composition, which is characterized in that: the medicinal composition comprises rehmannia root, szechwon tangshen root, common anemarrhena rhizome, prepared rehmannia root and stiff silkworm, and also comprises one or more of dwarf lilyturf tuber, tall gastrodia tuber, asparagus, Chinese angelica, honeycomb, scorpion, liquoric root and astragalus. The medicinal composition has the effect of treating skin diseases. In addition, the clinical trials show that the medicinal composition has excellent therapeutic effect.
Description
Technical field
The present invention relates to technical field of traditional Chinese medicine pharmacy, be specifically related to a kind of pharmaceutical composition.
Dermatosis of the present invention is meant skin pruritus due to the clinical common different reasons, psoriasis, eczema, dermatitis, seat skin ulcer etc.
Background technology
Skin is the maximum organ of human body, and it contacts the closest with the external world, so ill probability is higher; Add the quickening of modern's rhythm of life, irregular the reaching of diet often eaten delicious food savoury and the peppery irritable food of raw meat, caused dermopathic sickness rate to be ascendant trend year by year; Becoming a kind of modal high morbidity plants; Play is itched unbearably during state of an illness outbreak, lies awake all night, and has had a strong impact on patient's quality of life.Dermopathic morbidity and visceral dysfunction have substantial connection; The deficiency and excess of QI and blood; The invasion and attack of rheumatism pyretic toxicity and metabolism have determined dermopathic character again; Therefore on treating for skin disease, not only to pay attention to changes in surface and use external preparation, more will pay attention to interior change and regulate the whole body function, could obtain special effect.At present, treat dermopathic external preparation and contain the hormone composition mostly, this type of medicine can relief of symptoms; Can't eradicate; Oral hormone class medicine or intramuscular injection hormones injection are tantamount to " the drink chicken is quenched the thirst ", tend to cause remission when taking medicine, the vicious cycle of drug withdrawal postemphasis.
Motherland's medical science thinks that dermatosis and lung, kidney, the heart, spleen, large intestine channel are in close relations, how by the lung meridian heat in blood, and the diseases caused by exogenous pathogenic factor ailment said due to cold or exposure, heart channel latent heat is loved and is not gone.Pathogenic heat are violated skin outward, and upward smoked women's head-ornaments and play rash, or surfeit delicious food savoury, taste are received dysfunction of the spleen in transportation and transformation, give birth in damp and hot, accumulate heat-transformation of a specified duration, and are strongly fragrant in blood system, overflow in skin.Or dysfunction of the spleen in transportation, retention of water-damp in the body, the strongly fragrant expectorant that stagnates into for a long time, inside and outside two heresies are rich mutually; Fill in reason, send out and cause a disease in skin, so; Meet above-mentioned disease clinically, theoretical according to tcm treatment according to syndrome differentiation, adopt that wind heat attacks that skin, heat in blood lose and support, excessive noxious heat, retention of damp-heat in the interior person disease treat.
Summary of the invention
We find in clinical research; With Chinese medicine Radix Rehmanniae, Radix Codonopsis, the Rhizoma Anemarrhenae, Radix Rehmanniae Preparata, Bombyx Batryticatus is main, different according to disease, compatibility or other Chinese medicines that are incompatible; The treatment dermatosis; Obtained extraordinary therapeutic effect, used the approval widely that obtains the patient, had the effect of good treatment dermatosis at clinical department of dermatologry.
The present invention implements through following technical scheme.
A kind of pharmaceutical composition, it comprises Chinese medicine Radix Rehmanniae, Radix Codonopsis, the Rhizoma Anemarrhenae, Radix Rehmanniae Preparata, Bombyx Batryticatus.
Radix Rehmanniae 1-5 weight portion wherein, Radix Codonopsis 1-3 are measured part, Rhizoma Anemarrhenae 1-3 weight portion, Radix Rehmanniae Preparata 1-5 weight portion, Bombyx Batryticatus 0.5-2 weight portion.
Compositions also comprises one or more in Radix Ophiopogonis, Rhizoma Gastrodiae, Radix Asparagi, Radix Angelicae Sinensis, Nidus Vespae, Scorpio, Radix Glycyrrhizae, the Radix Astragali.
Radix Rehmanniae 1-5 weight portion wherein, Radix Codonopsis 1-3 are measured part, Rhizoma Anemarrhenae 1-3 weight portion, Radix Rehmanniae Preparata 1-5 weight portion; Bombyx Batryticatus 0.5-2 weight portion, Radix Ophiopogonis the 1-3 weight portion, Rhizoma Gastrodiae 0.1-1 weight portion; Radix Asparagi 1-3 weight portion, Radix Angelicae Sinensis 1-3 weight portion, Nidus Vespae 0.5-2 weight portion; Scorpio 0.1-1 weight portion, Radix Glycyrrhizae 1-3 weight portion, Radix Astragali 1-3 weight portion.
Radix Rehmanniae 3.33 weight portions wherein, Radix Codonopsis 1.67 amounts part, the Rhizoma Anemarrhenae 1.67 weight portions, Radix Rehmanniae Preparata 2.50 weight portions; Bombyx Batryticatus 1.00 weight portions, Radix Ophiopogonis 1.50 weight portion, Rhizoma Gastrodiae 0.50 weight portion; Radix Asparagi 1.50 weight portions, Radix Angelicae Sinensis 1.67 weight portions, Nidus Vespae 1.00 weight portions; Scorpio 0.50 weight portion, Radix Glycyrrhizae 1.67 weight portions, the Radix Astragali 1.67 weight portions.
The application of aforementioned pharmaceutical compositions in preparation treatment dermatosis medicine.
Aforementioned pharmaceutical compositions can be used as the crude drug of Chinese medicine decoction, also can be used as the crude drug of oral formulations such as tablet, capsule, oral liquid, granule.The preparation of above-mentioned preparation can prepare according to prior art, also can prepare according to following method: get Rhizoma Gastrodiae, Radix Angelicae Sinensis, astragalus membranaceus powder and be broken into fine powder, mixing; Get that it is 1/3 subsequent use, Chinese medicine extracting in waters such as all the other fine powders and Radix Rehmanniae, extracting solution filters; Concentrate, drying is pulverized; With above-mentioned remaining 2/3 fine powder mixing; Conventional method for preparing according to oral formulations is prepared into preparation, is used for the different skin diseases such as skin pruritus, psoriasis, eczema, dermatitis, seat skin ulcer due to the different reasons of clinical treatment, and effective percentage is high.
The check and analysis result of above-mentioned preparation meets the standard of the Pharmacopoeia of the People's Republic of China.
The clinical experiment example
Experiment 1
The present invention collects 200 routine cases (during clinical use pharmaceutical composition of the present invention, crude drug is maintained secrecy, and the patient can't learn its composition) altogether in dermatosis hospital, carries out clinical observation on the therapeutic effect.These cases are the out-patient, and wherein the male accounts for 41%, the women accounts for 59%, age 18-79 year, 52 years old mean age, the course of disease 1 thoughtful 1 year, average 12 weeks.Wherein eczema, dermatitis patients account for total case load 50% (acute, subacute eczema accounts for 80% of eczema, dermatitis case; Chronic eczema accounts for 30% of eczema, dermatitis case; Urticaria accounts for 15% of total case, and skin pruritus accounts for 40% of total case, and the seat skin ulcer accounts for 5% of total case; Psoriasis accounts for 10% of total case, is wind heat or damp-heat type.Subjective symptoms shows as pruritus, and erythra shows as erythema, pimple, oozes out erosion, scarlet or pale red welt, scratch, infiltration or lichen appearanceization.Light red tongue is yellow or yellow greasy, floating and rapid pulse, stringy and rolling pulse or sliding number.
Therapeutic Method: respectively obey the preparation of preparation of pharmaceutical compositions of the present invention every day sooner or later.
Curative effect determinate standard:
Cure: pruritus, strip off, ooze out and wait allergic symptom all to disappear, follow up a case by regular visits to not have in 6 months and recur.
Produce effects: pruritus, strip off, allergic symptom such as ooze out and all disappear or significantly improve.
Effectively: pruritus, strip off, ooze out etc. that allergic symptom is all more preceding to take a turn for the better to some extent.
Invalid: pruritus, strip off, allergic symptom such as oozing out does not all have improvement.
The result is following:
Eczematous dermatitis: after 8 weeks of taking medicine, the erythema color is thin out, the pimple decreased number, and infiltration or lichenization skin lesion alleviate to some extent, and rotten to the corn, sepage disappears, and pruritus obviously alleviates; Took medicine for 2 weeks, erythra disappears basically, pruritus transference cure, cure rate 92.7%, obvious effective rate 1.3%, effective percentage 6.1%.
Urticaria: take medicine after 2 weeks, pruritus alleviates, and idol has new breakout; Take medicine after 3 weeks, do not have new breakout, pruritus transference cure, cure rate 94.6%, effective percentage 1.1%, effective percentage 1.7%.
Skin pruritus: take medicine after 1 week, pruritus obviously alleviates: after 2 weeks of taking medicine, and the pruritus transference cure.
The seat skin ulcer: after 4 weeks of taking medicine, no New Development seat skin ulcer, transference cure, cure rate 94.6%, obvious effective rate 1.0%, effective percentage 5%.
Psoriasis: after 16 weeks of taking medicine, cure rate 81.3%, obvious effective rate 4.9%, effective percentage 1.4%.
Experiment 2
The present invention collects 350 routine cases (during clinical use pharmaceutical composition of the present invention, crude drug is maintained secrecy, and the patient can't learn its composition) altogether at another large-scale synthesis hospital dermatology department, carries out clinical observation on the therapeutic effect.
Cure: pruritus, strip off, ooze out and wait allergic symptom all to disappear, follow up a case by regular visits to not have in 6 months and recur.
Produce effects: pruritus, strip off, allergic symptom such as ooze out and all disappear or significantly improve.
Effectively: pruritus, strip off, ooze out etc. that allergic symptom is all more preceding to take a turn for the better to some extent.
Invalid: pruritus, strip off, allergic symptom such as oozing out does not all have improvement.
Clinical observation result: each patient follows other diseases different because state of an illness weight differs, and therefore, the course of treatment, length also was not quite similar, and after finishing the course of treatment, patient's curative effect situation is pressed curative effect determinate standard, through the medical statistics method, and result such as following table 1:
Table 1 medicine composite for curing result statistics of the present invention
| Group | Cure rate % | Obvious effective rate % | Effective percentage % | Inefficiency % |
| Dermatitis | 97.6 | 1.1 | 1.3 | 0 |
| Eczema | 90.9 | 8.5 | 0.6 | 0 |
| Psoriasis | 79.9 | 18.3 | 0.5 | 0.4 |
| Urticaria | 90.6 | 2.7 | 6.7 | 0 |
| The seat skin ulcer | 98.1 | 0.9 | 1.0 | 0 |
Preparation embodiment
Embodiment 1
Pharmaceutical composition is: Radix Rehmanniae, Radix Codonopsis, the Rhizoma Anemarrhenae, Radix Rehmanniae Preparata, Bombyx Batryticatus.
Or: pharmaceutical composition is: Radix Rehmanniae, Radix Codonopsis, the Rhizoma Anemarrhenae, Radix Rehmanniae Preparata, Bombyx Batryticatus, Radix Ophiopogonis.
Or: pharmaceutical composition is: Radix Rehmanniae, Radix Codonopsis, the Rhizoma Anemarrhenae, Radix Rehmanniae Preparata, Bombyx Batryticatus, Radix Ophiopogonis, Rhizoma Gastrodiae, Radix Asparagi, Radix Angelicae Sinensis.
Or: pharmaceutical composition is: Radix Rehmanniae, Radix Codonopsis, the Rhizoma Anemarrhenae, Radix Rehmanniae Preparata, Bombyx Batryticatus, Radix Ophiopogonis, Rhizoma Gastrodiae, Scorpio, Radix Glycyrrhizae, the Radix Astragali.
Or: pharmaceutical composition is: Radix Rehmanniae, Radix Codonopsis, the Rhizoma Anemarrhenae, Radix Rehmanniae Preparata, Bombyx Batryticatus, Rhizoma Gastrodiae, Radix Angelicae Sinensis, Scorpio, Radix Glycyrrhizae.
Or: pharmaceutical composition is: Radix Rehmanniae, Radix Codonopsis, the Rhizoma Anemarrhenae, Radix Rehmanniae Preparata, Bombyx Batryticatus, Radix Ophiopogonis, Rhizoma Gastrodiae, Radix Asparagi, Radix Angelicae Sinensis, Nidus Vespae, Scorpio, Radix Glycyrrhizae, the Radix Astragali.
Or: pharmaceutical composition is: Radix Rehmanniae, Radix Codonopsis, the Rhizoma Anemarrhenae, Radix Rehmanniae Preparata, Bombyx Batryticatus, Radix Ophiopogonis, Rhizoma Gastrodiae, Radix Asparagi, Radix Angelicae Sinensis, Nidus Vespae, Scorpio, Radix Glycyrrhizae.
Or: pharmaceutical composition is: Radix Rehmanniae, Radix Codonopsis, the Rhizoma Anemarrhenae, Radix Rehmanniae Preparata, Bombyx Batryticatus, Radix Ophiopogonis, Rhizoma Gastrodiae, Radix Angelicae Sinensis, Scorpio, the Radix Astragali.
Or: pharmaceutical composition is: in Radix Rehmanniae, Radix Codonopsis, the Rhizoma Anemarrhenae, Radix Rehmanniae Preparata, Bombyx Batryticatus, Radix Ophiopogonis, Rhizoma Gastrodiae, Radix Asparagi, Radix Angelicae Sinensis, Nidus Vespae, Scorpio, Radix Glycyrrhizae, the Radix Astragali.
Or: pharmaceutical composition is: Radix Rehmanniae, Radix Codonopsis, the Rhizoma Anemarrhenae, Radix Rehmanniae Preparata, Bombyx Batryticatus, Flos Lonicerae.
Or: pharmaceutical composition is: Radix Rehmanniae, Radix Codonopsis, the Rhizoma Anemarrhenae, Radix Rehmanniae Preparata, Bombyx Batryticatus, Flos Chrysanthemi, Fructus Forsythiae
Embodiment 2
Pharmaceutical composition comprises: Radix Rehmanniae 100g, Radix Codonopsis 100g, Rhizoma Anemarrhenae 100g, Radix Rehmanniae Preparata 100g, Bombyx Batryticatus 50g.
Or: pharmaceutical composition comprises: Radix Rehmanniae 500g, Radix Codonopsis 300g, Rhizoma Anemarrhenae 300g, Radix Rehmanniae Preparata 500g, Bombyx Batryticatus 200g.
Or: pharmaceutical composition comprises: Radix Rehmanniae 150g, Radix Codonopsis 120g, Rhizoma Anemarrhenae 140g, Radix Rehmanniae Preparata 140g, Bombyx Batryticatus 60g.
Or: pharmaceutical composition comprises: Radix Rehmanniae 450g, Radix Codonopsis 290g, Rhizoma Anemarrhenae 280g, Radix Rehmanniae Preparata 450g, Bombyx Batryticatus 190g.
Or: pharmaceutical composition comprises: Radix Rehmanniae 490g, Radix Codonopsis 120g, Rhizoma Anemarrhenae 190g, Radix Rehmanniae Preparata 450g, Bombyx Batryticatus 55g.
Or: pharmaceutical composition comprises: Radix Rehmanniae 475g, Radix Codonopsis 280g, Rhizoma Anemarrhenae 295g, Radix Rehmanniae Preparata 105g, Bombyx Batryticatus 60g.
Embodiment 3
Radix Rehmanniae 100g, Radix Codonopsis 100g, Rhizoma Anemarrhenae 100g, Radix Rehmanniae Preparata 100g, Bombyx Batryticatus 50g, Radix Ophiopogonis 100g, Rhizoma Gastrodiae 10g, Radix Asparagi 100g, Radix Angelicae Sinensis 100g, Nidus Vespae 50g, Scorpio 10g, Radix Glycyrrhizae 100g, Radix Astragali 100g.
Embodiment 4
Radix Rehmanniae 500g, Radix Codonopsis 300g, Rhizoma Anemarrhenae 300g, Radix Rehmanniae Preparata 500g, Bombyx Batryticatus 200g, Radix Ophiopogonis 300g, Rhizoma Gastrodiae 100g, Radix Asparagi 300g, Radix Angelicae Sinensis 300g, Nidus Vespae 200g, Scorpio 100g, Radix Glycyrrhizae 300g, Radix Astragali 300g.
Embodiment 5
Radix Rehmanniae 150g, Radix Codonopsis 120g, Rhizoma Anemarrhenae 120g, Radix Rehmanniae Preparata 150g, Bombyx Batryticatus 60g, Radix Ophiopogonis 120g, Rhizoma Gastrodiae 15g, Radix Asparagi 115g, Radix Angelicae Sinensis 150g, Nidus Vespae 55g, Scorpio 20g, Radix Glycyrrhizae 150g, Radix Astragali 150g.
Embodiment 6
Radix Rehmanniae 490g, Radix Codonopsis 280g, Rhizoma Anemarrhenae 250g, Radix Rehmanniae Preparata 175g, Bombyx Batryticatus 180g, Radix Ophiopogonis 270g, Rhizoma Gastrodiae 90g, Radix Asparagi 265g, Radix Angelicae Sinensis 280g, Nidus Vespae 175g, Scorpio 80g, Radix Glycyrrhizae 295g, Radix Astragali 245g.
Embodiment 7
Radix Rehmanniae 333g, Radix Codonopsis 167g, Rhizoma Anemarrhenae 167g, Radix Rehmanniae Preparata 250g, Bombyx Batryticatus 100g, Radix Ophiopogonis 150g, Rhizoma Gastrodiae 50g, Radix Asparagi 150g, Radix Angelicae Sinensis 167g, Nidus Vespae 100g, Scorpio 50g, Radix Glycyrrhizae 167g, Radix Astragali 167g.
The application of aforementioned pharmaceutical compositions in preparation treatment dermatosis medicine.
Aforementioned pharmaceutical compositions can be used as the crude drug of Chinese medicine decoction, also can be used as the crude drug of oral formulations such as tablet, capsule, oral liquid, granule.The preparation of above-mentioned preparation can prepare according to prior art, also can prepare according to following method: get Rhizoma Gastrodiae, Radix Angelicae Sinensis, astragalus membranaceus powder and be broken into fine powder, mixing; Get that it is 1/3 subsequent use, Chinese medicine extracting in waters such as all the other fine powders and Radix Rehmanniae, extracting solution filters; Concentrate, drying is pulverized; With above-mentioned remaining 2/3 fine powder mixing; Conventional method for preparing according to oral formulations is prepared into preparation, is used for the different skin diseases such as skin pruritus, psoriasis, eczema, dermatitis, seat skin ulcer due to the different reasons of clinical treatment, and effective percentage is high.
The check and analysis result of above-mentioned preparation meets the standard of the Pharmacopoeia of the People's Republic of China.
Claims (1)
1. the dermopathic medicine compositions of treatment is characterized in that pharmaceutical composition consists of: Radix Rehmanniae 3.33 weight portions, Radix Codonopsis 1.67 amount parts, the Rhizoma Anemarrhenae 1.67 weight portions; Radix Rehmanniae Preparata 2.50 weight portions, Bombyx Batryticatus 1.00 weight portions, Radix Ophiopogonis 1.50 weight portion, Rhizoma Gastrodiae 0.50 weight portion; Radix Asparagi 1.50 weight portions, Radix Angelicae Sinensis 1.67 weight portions, Nidus Vespae 1.00 weight portions; Scorpio 0.50 weight portion, Radix Glycyrrhizae 1.67 weight portions, the Radix Astragali 1.67 weight portions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101181437A CN101647943B (en) | 2008-08-13 | 2008-08-13 | Medicinal composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101181437A CN101647943B (en) | 2008-08-13 | 2008-08-13 | Medicinal composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101647943A CN101647943A (en) | 2010-02-17 |
| CN101647943B true CN101647943B (en) | 2012-06-27 |
Family
ID=41670341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101181437A Active CN101647943B (en) | 2008-08-13 | 2008-08-13 | Medicinal composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101647943B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102139063A (en) * | 2011-03-18 | 2011-08-03 | 车莉 | Traditional Chinese medicine composition for treating seborrheic dermatitis |
| CN105395899A (en) * | 2015-11-18 | 2016-03-16 | 中国医学科学院医药生物技术研究所 | External use dosage form of gastrodia elata |
-
2008
- 2008-08-13 CN CN2008101181437A patent/CN101647943B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN101647943A (en) | 2010-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101214345B (en) | Chinese medicine preparation for treating various itching skin diseases such as eczema dermatitis, urticaria and etc. | |
| CN103341145B (en) | Traditional Chinese medicine for treating psoriasis and preparation method thereof | |
| CN1927379A (en) | Traditional medicine preparation for treating children's pulmonary disease | |
| CN102188685B (en) | Externally-applied traditional Chinese medicine powder for treating diarrhea type irritable bowel syndrome and preparation method thereof | |
| CN103169883B (en) | Traditional Chinese medicine for treating infantile jaundice | |
| CN101647943B (en) | Medicinal composition | |
| CN103948782A (en) | Pharmaceutical composition for treating hyperplasia of mammary glands due to stagnation of liver qi as well as preparation method and application of pharmaceutical composition | |
| CN101342360B (en) | Chinese medicinal composition for treating esophagus cancer | |
| CN103638335B (en) | A kind of Chinese medicine for the treatment of refractory acne and preparation method thereof | |
| CN101647935B (en) | Medicinal composition | |
| CN104758900A (en) | Traditional Chinese medicine for treating acute pancreatitis | |
| CN104398912A (en) | Medicine capable of moistening lung, relieving cough and reducing sputum and preparation method of medicine | |
| CN103463604A (en) | Drug for treating cough and asthma | |
| CN100404061C (en) | Chinese medicinal composition for treating chronic pharygitis | |
| CN103006955B (en) | Traditional Chinese medicine composition for treating asthma | |
| CN105902897A (en) | Pharmaceutical preparation for treating pancreatic cancer and application thereof | |
| CN105169149A (en) | Traditional Chinese medicine composition for treating pyrophlegm stasis accumulation type thyroid cancer, preparation method and application | |
| CN104399040A (en) | Drug for treating gastrectasia and preparation method thereof | |
| CN1222364A (en) | Serial medicines for curing cancer through oral taking, dressing and medicated diet and preparation thereof | |
| CN103494939A (en) | Traditional Chinese medicine for treating senile habitual constipation | |
| CN101618187A (en) | Medicine for treating liver cancer and preparation method thereof | |
| CN101983712A (en) | Novel medicament for treating coronary heart disease | |
| CN101112508A (en) | Chinese traditional medicine for treating children attention deficit disorder | |
| CN105311468A (en) | Traditional Chinese medicine composition for treating lymph cancer and preparation method thereof | |
| CN103637349B (en) | Functional beverage capable of removing dampness and tonifying deficiency and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |